Clinical trials: STEMI
STEMI - ST-segment Elevation Myocardial Infarction
Metabolic Characteristics of Plasma OxPLs in STEMI Patients.
The goal of this observational study is to investigate the structural composition and metabolic characteristics of OxPLs in ST-segment elevation myocardial infarction(STEMI) patients.
- Trial name
- NCT07382700
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
ST Elevation Myocardial Infarction (STEMI)
IMPROVE-STEMI: pPCI Plus Low-dose r-SK in STEMI
This is a multicenter, prospective, pragmatic, randomized controlled trial (IMPROVE-STEMI) aiming to evaluate the efficacy and safety of intracoronary low-dose recombinant streptokinase combined with primary percutaneous coronary…
- Trial name
- IMPROVE-STEMI (NCT07875179)
- Testing
- Recombinant Streptokinase
- Where
- China
- Volunteers
- 3,300 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
ST Elevation (STEMI) Myocardial Infarction, Microvascular Obstruction (MVO)
Multimodality Assessment of Myocardial Reperfusion After Primary Percutaneous Coronary Intervention
This study aims to evaluate myocardial reperfusion in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
- Trial name
- NCT07876791
- Volunteers
- 90 people
- Sponsor
- Assiut University
Acute Coronary Syndromes (ACS), Ventricular Tachycardia (VT)
Analysis of Life-threatening ARrhythMias After Acute Coronary Syndrome
Patients admitted with an acute coronary syndrome (ACS) are at increased risk of malignant cardiac arrhythmias (MA), such as sustained ventricular tachycardia and ventricular fibrillation.
- Conditions
- Acute Coronary Syndromes (ACS), Ventricular Tachycardia (VT), Ventricular Fibrillation, Pulseless Electrical Activity
- Trial name
- ALARM-ACS (NCT07824050)
- Where
- Netherlands
- Volunteers
- 2,775 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
ST-elevation Myocardial Infarction (STEMI), Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the…
- Trial name
- CHIP in STEMI (NCT07615023)
- Testing
- Clonal hematopoiesis assessment and cardiac magnetic resonance imaging
- Where
- Austria
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
STEMI, NSTEMI
Prediction of Adverse Events From Non-PCI Coronary Plaques Using Machine Learning
The aim of our project is to predict, with the help of artificial intelligence (AI) and machine learning techniques, the natural history of non-flow-limiting coronary stenoses and to develop and validate a machine learning risk…
- Conditions
- STEMI, NSTEMI, Chronic Coranary Sindrome, Unstable Angina (UA)
- Trial name
- Predict AI (NCT07866144)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Myocardial Infarction, Reperfusion Injury
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI).
- Conditions
- Myocardial Infarction, Reperfusion Injury, AMI, STEMI (ST Elevation MI)
- Trial name
- PROTECT-MI (NCT07362446)
- Testing
- Xolatryp
- Where
- 8 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Nyrada Pty Ltd
Acute STEMI, PPCI
On vs Off-hour PPCI in STEMI Patients
ST-elevation myocardial infarction (STEMI) remains a leading cause of morbidity and mortality globally, and timely reperfusion with primary percutaneous coronary intervention (PPCI) is the gold-standard treatment1.
- Conditions
- Acute STEMI, PPCI, Observational Study, Coronary Artery Disease (CAD)
- Trial name
- On vs Off PPCI (NCT07860086)
- Where
- Egypt
- Volunteers
- 450 people
- Sponsor
- Assiut University
STEMI - ST Elevation Myocardial Infarction (MI), Primary PCI - STEMI
Early Intracoronary N-Acetylcysteine During Primary PCI in STEMI: A Pilot Randomized Trial of Reperfusion Injury Biomarkers and Functional Recovery
Myocardial ischemia-reperfusion injury still poses a major therapeutic challenge in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
- Trial name
- NCT06850831
- Testing
- Antipac
- Where
- Indonesia
- Volunteers
- 110 people
- Sponsor
- dr. Ahmad Yasa, Sp.JP, Subsp.K.I.(K), M.Kes, FIHA, FasCC, FA
ST-elevation Myocardial Infarction (STEMI)
Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction
Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term…
- Trial name
- DCB-STEMI (NCT06742125)
- Testing
- Drug-coated balloon (DCB), Drug-eluting stent (DES)
- Where
- China
- Volunteers
- 1,244 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
CHIP in Health and Disease
Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic…
- Conditions
- Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndrome
- Trial name
- CHIP2 (NCT07780552)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
ST Elevation (STEMI) Myocardial Infarction, Contrast Induced Nephropathy (CIN)
Beyond the Mehran Risk Score: Predictive Value of Total Ischemic Time for Contrast-Induced Nephropathy in ST Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention.
Contrast-Induced Nephropathy (CIN) is a serious complication following primary percutaneous coronary intervention (PCI) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI).
- Conditions
- ST Elevation (STEMI) Myocardial Infarction, Contrast Induced Nephropathy (CIN), Acute Kidney Injury
- Trial name
- NCT07826572
- Testing
- Total Ischemic Time Evaluation
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Assiut University
ST-segment Elevation Myocardial Infarction (STEMI)
Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial
The purpose of this study was to evaluate the efficacy and safety of fexofenadine hydrochloride on the basis of standard treatment after PCI in STEMI patients.
- Trial name
- FEND-AMI (NCT06548204)
- Testing
- Fexofenadine Hydrochloride
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Cardiogenic Shock Acute, STEMI - ST Elevation Myocardial Infarction
Hong Kong Cardiogenic Shock Initiative
Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is a severe condition with high mortality. Early revascularization and Impella device (Abiomed) support improve outcomes.
- Conditions
- Cardiogenic Shock Acute, STEMI - ST Elevation Myocardial Infarction, Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction
- Trial name
- HK CSI (NCT07323238)
- Where
- Hong Kong
- Volunteers
- 320 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
Myocardial Infarction (MI), Cardiogenic Shock
Optimal Timing of Microaxial Flow Pump(Impella CP) in AMI-related Cardiogenic Shock
PRIME-SHOCK is a prospective, single-center, open-label, randomized, superiority trial. Eligible participants with AMICS and a clinical decision to use Impella CP will be randomized in a 1:1 ratio before culprit-lesion PCI.
- Conditions
- Myocardial Infarction (MI), Cardiogenic Shock, ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
- Trial name
- PRIME-SHOCK (NCT07817472)
- Testing
- Routine pre-PCI Impella CP, Selective post-PCI Impella CP
- Where
- South Korea
- Volunteers
- 126 people
- Sponsor
- Chonnam National University Hospital
ST-segment Elevation Myocardial Infarction (STEMI)
Thrombus Aspiration in STEMI Patients With High Thrombus Burden
This is a prospective, multicenter, open-label, randomized, controlled, parallel group study, in which ST-segment Elevation Myocardial Infarction (STEMI) patients with high thrombus burden(TIMI thrombus grade ≥3) are included.
- Trial name
- NCT04212494
- Testing
- Thrombus aspiration, PCI Alone
- Where
- 50 sites in China
- Volunteers
- 3,838 people
- Sponsor
- Guangdong Provincial People's Hospital
ST Elevation Myocardial Infarction (STEMI), Acute Coronary Syndromes (ACS)
A Single-Center, Retrospective, Propensity-Score-Matched Cohort Study Comparing Drug-Coated Balloon Versus Drug-Eluting Stent for Reducing Immediate Post-Procedural Slow-Flow/No-Reflow in Acute ST-Elevation Myocardial Infarction Patients With High Thrombus Burden
This is a single-center, retrospective, propensity-score-matched observational study. It aims to compare the rate of immediate slow-flow or no-reflow after percutaneous coronary intervention (PCI) between drug-coated balloon…
- Trial name
- STEMI-DCB (NCT07806370)
- Testing
- Drug-Coated Balloon (DCB), Drug-Eluting Stent (DES)
- Where
- China
- Volunteers
- 668 people
- Sponsor
- Xijing Hospital
Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI)
Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI
The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial…
- Conditions
- Myocardial Infarction (MI), ST-Segment Elevation Myocardial Infarction(STEMI), NSTEMI - Non-ST-Segment Elevation Myocardial Infarction, AF - Atrial Fibrillation
- Trial name
- HERO-AF-AMI (NCT07583784)
- Testing
- DAT (DOAC+clopidogrel), DOAC monotherapy
- Where
- South Korea
- Volunteers
- 860 people
- Sponsor
- Chonnam National University Hospital
STEMI - ST-segment Elevation Myocardial Infarction, Chest Pain
SMARTwatch for the Diagnosis of ST-segment Elevation Myocardial Infarction in Patients With Chest Pain
The main symptom that initiates the diagnostic and therapeutic process for patients with suspected acute coronary syndrome is chest pain.
- Trial name
- SMART-CART-AMI (NCT07780942)
- Testing
- ECG smartwatch recording
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital General Universitario Santa Lucia
STEMI - ST Elevation Myocardial Infarction, AMI
SuperSaturated Oxygen Comprehensive Observational Registry
The SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE) registry, a prospectively designed observational study, aims to evaluate the clinical utility, infarct size reduction, and cost-effectiveness of SSO2 Therapy…
- Trial name
- SSCORE (NCT06438315)
- Testing
- KCCQ, Eq5D, cMRI (Subset of patients)
- Where
- 25 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TherOx